ImmuPharma (LON:IMM) Stock Price Up 28.8% - Time to Buy?

Key Points

• ImmuPharma's stock price surged by 28.8%, reaching a high of GBX 15.23 ($0.21) during mid-day trading, significantly higher than its previous close of GBX 10.85 ($0.15).
• The stock's trading volume increased by 451% compared to its average session volume, with nearly 44.8 million shares changing hands.
• ImmuPharma reports a market cap of £69.86 million and analysts predict a negative earnings per share of approximately -339 for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 28.8% on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares were traded during mid-day trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Up 28.8%

The stock has a market cap of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The stock's 50 day moving average price is GBX 3.12 and its two-hundred day moving average price is GBX 2.93.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.